Systematic review and benchmarking of Quality-Adjusted Time Without Symptoms or Toxicity (Q-TWiST) in oncology

References

• Glasziou PP, Cole BF, Gelber RD, et al. Quality adjusted survival analysis with repeated quality of life measures. Stat Med. 1998;17(11):1215–1229.
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A. A new endpoint for the assessment of adjuvant therapy in postmenopausal women with operable breast cancer. J Clin Oncol. 1986;4(12):1772–1779.
   PubMed Web of Science ®Google Scholar
• Cole BF, Gelber RD, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14(10):2666–2673.
   PubMed Web of Science ®Google Scholar
• Cole BF, Glantz MJ, Jaeckle KA, et al. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer. 2003;97(12):3053–3060.
   PubMed Web of Science ®Google Scholar
• Gao F, Wee J, Wong HB, et al. Quality-of-life-adjusted survival analysis of concurrent chemo radiotherapy for locally advanced (nonmetastatic) nasopharyngeal cancer. Int J Radiat Oncol Biol Phys. 2010;78(2):454–460.
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A, Cole BF, et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst. 1996;88(15):1039–1045.
   PubMedGoogle Scholar
• Jang RW, Le Maitre A, Ding K, et al. Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial. J Clin Oncol. 2009;27(26):4268–4273.
   PubMed Web of Science ®Google Scholar
• Gelber RD, Lenderking WR, Cotton DJ, et al. Quality-of-life evaluation in a clinical trial of zidovudine therapy in patients with mildly symptomatic HIV infection. The AIDS Clinical Trials Group. Ann Intern Med. 1992;116(12 Pt 1):961–966.
   PubMed Web of Science ®Google Scholar
• Schwartz CE, Coulthard-Morris L, Cole B, et al. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol. 1997;54(12):1475–1480.
   PubMedGoogle Scholar
• Schwartz CE, Cole BF, Vickrey BG, et al. The Q-TWiST approach to assessing health-related quality of life in epilepsy. Qual Life Res. 1995;4(2):135–141.
   PubMed Web of Science ®Google Scholar
• Gelber RD, Cole BF, Gelber S, et al. Comparing treatments using quality-adjusted survival: the Q-TWiST method. Am Stat. 1995;49(2):161–169.
   Web of Science ®Google Scholar
• Revicki DA, Feeny D, Hunt TL, et al. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res. 2006;15(3):411–423.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Targeted cancer therapies 2017 [cited June 28, 2017]. Available from: https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies/targeted-therapies-fact-sheet
   Google Scholar
• Tate WR, Skrepnek GH. Quality-adjusted time without symptoms or toxicity (Q-TWiST): patient-reported outcome or mathematical model? A systematic review in cancer. Psychooncology. 2015;24(3):253–261.
   PubMed Web of Science ®Google Scholar
• Stephens R. Clinically important differences in Q-TWIST – one twist too many? Qual Life Res. 2006;15(3):425–426.
   PubMed Web of Science ®Google Scholar
• Beaumont JL, Salsman JM, Diaz J, et al. Quality-adjusted time without symptoms or toxicity analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122(7):1108–1115.
   PubMed Web of Science ®Google Scholar
• Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol. 2015;38(4):422–430.
   PubMed Web of Science ®Google Scholar
• Reni M, Wan Y, Solem C, et al. Quality-adjusted survival with combination nab-paclitaxel + gemcitabine vs gemcitabine alone in metastatic pancreatic cancer: a Q-TWiST analysis. J Med Econ. 2014;17(5):338–346.
   PubMedGoogle Scholar
• Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy for premenopausal breast cancer: a meta-analysis using quality-adjusted survival. Cancer J Sci Am. 1995;1(2):114–121.
   PubMedGoogle Scholar
• Marcus R, Aultman R, Jost F. A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin’s lymphoma. Br J Cancer. 2010;102(1):19–22.
   PubMed Web of Science ®Google Scholar
• Sherrill B, Amonkar MM, Stein S, et al. Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. Br J Cancer. 2008;99(5):711–715.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao Z, Barber B, et al. A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer. Br J Cancer. 2011;104(12):1848–1853.
   PubMed Web of Science ®Google Scholar
• Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96:5–21.
   PubMed Web of Science ®Google Scholar
• Neumann PJ. What next for QALYs? JAMA. 2011;305(17):1806–1807.
   PubMed Web of Science ®Google Scholar
• Fayers PM, Machin D. Clinical interpretation. Quality of life: the assessment, analysis and reporting of patient-reported outcomes. 3rd ed. Chichester, UK: John Wiley & Sons, Ltd; 2015. p. 475–509.
   Google Scholar
• Krabbe P. The measurement of health and health status: concepts, methods and applications from a multidisciplinary perspective. San Diego: Elsevier/Academic Press; 2016.
   Google Scholar
• Weeks J. Measurement of utilities and quality-adjusted survival. Oncology (Williston Park). 1995;9(11 Suppl):67–70.
   PubMedGoogle Scholar
• Hao Y, Wolfram V, Cook J. A structured review of health utility measures and elicitation in advanced/metastatic breast cancer. Clinicoecon Outcomes Res. 2016;8:293–303.
   PubMed Web of Science ®Google Scholar
• Schnipper LE, Davidson NE, Wollins DS, et al. Updating the American Society of Clinical Oncology Value Framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–2934.
   PubMed Web of Science ®Google Scholar
• Cole BF, Kilbridge KL. Quality-adjusted survival analysis in cancer clinical trials. Statistical methods for quality of life studies. Boston, MA: Springer; 2002.
   Google Scholar
• Postmus D, Richard S, Bere N, et al. Individual trade-offs between possible benefits and risks of cancer treatments: results from a stated preference study with patients with multiple myeloma. Oncologist. 2017;23(1):44–51.
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Morris MJ, Hodi FS, et al. When progressive disease does not mean treatment failure: reconsidering the criteria for progression. J Natl Cancer Inst. 2012;104(20):1534–1541.
   PubMedGoogle Scholar
• Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33(31):3541–3543.
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15(23):7412–7420.
   PubMed Web of Science ®Google Scholar
• Gelber RD, Goldhirsch A, Cole BF. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials. 1993;14(6):485–499.
   PubMedGoogle Scholar
• Cole BF, Gelber RD, Anderson KM. Parametric approaches to quality-adjusted survival analysis. International Breast Cancer Study Group. Biometrics. 1994;50(3):621–631.
   PubMed Web of Science ®Google Scholar
• Harris SJ, Brown J, Lopez J, et al. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med. 2016;13(2):171–193.
   PubMed Web of Science ®Google Scholar
• Majer IM, Gueron B, Kotapati S, et al. Extrapolating survival in a heterogeneous patient population with metastatic melanoma; a case study of integrating statistical and clinical consideration. Value Health. 2013;16(7):A594.
   Web of Science ®Google Scholar